In 2022, we more than doubled Phexxi revenue while cutting costs 42%. That was good, but not enough to get us to break-even.
Evofem Biosciences Reports Year-End 2022 Financial Results and Provides Corporate Update Read More »
ImmunoGen, Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, reviewed recent progress in the business and reported financial results for the quarter ended March 31, 2023.
ImmunoGen Reports Recent Progress and First Quarter 2023 Financial Results Read More »
Inmagene Biopharmaceuticals announced positive topline results from a Phase 1 study evaluating IMG-004 in healthy participants.
Ossium Health, Inc. announced that the California Institute of Regenerative Medicine has awarded the company a $3.46M Clinical Stage Research Program grant to support the continued clinical development of OSSM-007, Ossium’s interferon-gamma primed mesenchymal stem cell product, for the treatment of steroid-refractory acute graft versus host disease.
RaySearch Laboratories AB publishes its Annual Report for the financial year 2022.
Hemogenyx Pharmaceuticals plc, the biopharmaceutical group developing new therapies and treatments for deadly blood diseases, announces its results for the year ended 31 December 2022.
En este Short averiguaremos de dónde procede el sonido agudo o zumbido que en ocasiones oímos. …
Otsuka America Pharmaceutical, Inc. and Lundbeck announce the U.S. Food and Drug Administration has approved the New Drug Application for ABILIFY ASIMTUFII® extended-release injectable suspension for intramuscular use, a once-every-two-months injection for the treatment of schizophrenia in adults or for maintenance monotherapy treatment of bipolar I disorder in adults.
Aditum Bio, the biotech investment firm cofounded in 2019 by former Novartis CEO Joe Jimenez and former President of the Novartis Institutes for BioMedical Research Dr. Mark Fishman, announced the formation of Vitalli Bio, a portfolio company created for the development of novel therapies for immunological disorders.
Aditum Bio Announces Formation of Vitalli Bio, Focused on Immunological Disorders Read More »
CEL-SCI Corporation, a Phase 3 cancer immunotherapy company, announced the pricing of its underwritten confidentially marketed public offering of 794,117 shares of common stock at an offering price of $1.70 per share.
